ClinVar Miner

Submissions for variant NM_004621.6(TRPC6):c.523C>T (p.Arg175Trp)

dbSNP: rs869025541
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Blueprint Genetics RCV000208455 SCV000264268 uncertain significance Nephrotic syndrome 2015-01-19 criteria provided, single submitter clinical testing
Athena Diagnostics Inc RCV000713890 SCV000844530 pathogenic not provided 2022-01-17 criteria provided, single submitter clinical testing This variant was not reported in large, multi-ethnic, general populations (http://gnomad.broadinstitute.org). This variant has been identified in multiple unrelated individuals with clinical features associated with this gene, including multiple apparent de novo cases. At least one other missense variant at this codon is considered to be pathogenic or likely pathogenic, suggesting this variant may also cause disease. Computational tools predict that this variant is damaging.
Baylor Genetics RCV001336716 SCV001530178 pathogenic Focal segmental glomerulosclerosis 2 2018-02-14 criteria provided, single submitter clinical testing This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. This variant has been previously reported as a de novo change in a patient with focal segmental glomerulosclerosis [PMID 28204945]
Servicio Canario de Salud, Hospital Universitario Nuestra Sra. de Candelaria RCV001336716 SCV002756473 pathogenic Focal segmental glomerulosclerosis 2 2022-11-29 criteria provided, single submitter clinical testing The c.523C>T (p.Arg175Trp) TRPC6 variant has been reported in our laboratory in a 9-year-old girl with suspected focal segmental glomerulosclerosis associated with hypertensive crisis, requiring daily dialysis. Previous episode of 3 months of progressive decline with the last 3 weeks of refusal to eat and vomiting. Negative autoimmune study, proteinuria in the nephrotic range, hypocalcemia and hyperphosphatemia. Her father received a kidney transplant at 9 and 37 years of age. This variant is a de novo change in her father (healthy grandparents, aunt, and 15-year-old brother do not have the variant) and it has been previously reported as a de novo change in a patient with focal segmental glomerulosclerosis [PMID 28204945] and in two patients with steroid resistant nephrotic syndrome [PMID 28117080, 26668027]. In summary, c.523C>T TRPC6 variant meets our criteria to be classified as pathogenic based upon its absence from controls (gnomAD no frequency), computational evidence of pathogenicity (CADD, MutationTaster, SIFT, PolyPhen2), de novo occurrence in this family and specific patient´s phenotype.
PreventionGenetics, part of Exact Sciences RCV003422116 SCV004116831 pathogenic TRPC6-related condition 2023-04-03 criteria provided, single submitter clinical testing The TRPC6 c.523C>T variant is predicted to result in the amino acid substitution p.Arg175Trp. This variant has been reported in multiple individuals with focal segmental glomerulosclerosis (de novo in Wang et al. 2017. PubMed ID: 28204945; Bierzynska et al. 2017. PubMed ID: 28117080; de novo in Nagano et al. 2020. PubMed ID: 31937884; de novo in Hanafusa et al. 2021. PubMed ID: 33884742). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Of note, different substitutions at the same codon (p.Arg175Gln and p.Arg175Gly) have been reported to be pathogenic for focal segmental glomerulosclerosis (Hofstra et al. 2013. PubMed ID: 23291369; Table S2, Park et al. 2020. PubMed ID: 32604935 ). The c.523C>T (p.Arg175Trp) variant is interpreted as pathogenic.
Sydney Genome Diagnostics, Children's Hospital Westmead RCV000208455 SCV001449461 likely pathogenic Nephrotic syndrome 2018-03-22 no assertion criteria provided clinical testing This individual is heterozygous for the c.523C>T p.(Arg175Trp) variant in the TRPC6 gene. To our knowledge, this variant has not been reported in any population databases (i.e. gnomAD, ExAC, ESP or dbSNP). This variant has been reported in three patients with steroid resistant nephrotic syndrome (Bierzynska et al 2017 Kidney Int 91:937-947 PMID: 28117080; Wang et al 2017 Pediatr Nephrol 32:1181-1192 PMID:28204945; Buscher et al 2016 Clin J Am Soc Nephrol 11:245-253 PMID: 26668027). The first two papers reported the variant as de novo/sporadic in the patient. In silico analysis (through Alamut Visual v2.8.1) using PolyPhen2, SIFT and MutationTaster all predict this variant to be a likely pathogenic variant. This variant is considered to be likely pathogenic according to the ACMG guidelines.
Yale Center for Mendelian Genomics, Yale University RCV000208455 SCV002107059 likely pathogenic Nephrotic syndrome 2017-11-10 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.